Core Viewpoint - The company reported a slight decline in revenue for the third quarter, while net profit showed a modest increase, indicating mixed performance in the latest financial results [1] Financial Performance - Q3 revenue was 74.3192 million yuan, a year-on-year decrease of 1.22% [1] - Q3 net profit was 31.2339 million yuan, a year-on-year increase of 1.94% [1] - Revenue for the first three quarters was 175 million yuan, a year-on-year increase of 1.07% [1] - Net profit for the first three quarters was 64.2107 million yuan, a year-on-year increase of 2.01% [1]

Group 1 - On September 25, 2023, Siron Biotech experienced a decline of 0.99% with a trading volume of 17.9856 million yuan [1] - The financing data for Siron Biotech on the same day showed a financing purchase amount of 1.4958 million yuan and a financing repayment of 2.0808 million yuan, resulting in a net financing buy of -0.5850 million yuan [1] - As of September 25, 2023, the total balance of margin trading for Siron Biotech was 155 million yuan, with the financing balance accounting for 6.19% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - As of June 30, 2023, the number of shareholders for Siron Biotech was 7,724, an increase of 9.39% from the previous period, while the average circulating shares per person decreased by 8.58% to 5,744 shares [2] - For the first half of 2023, Siron Biotech reported an operating income of 101 million yuan, representing a year-on-year growth of 2.82%, and a net profit attributable to shareholders of 32.9767 million yuan, up 2.07% year-on-year [2] - Since its A-share listing, Siron Biotech has distributed a total of 248 million yuan in dividends, with 150 million yuan distributed over the past three years [2]

Group 1 - The company, Sairun Biotech (688163.SH), has stated that it currently has no plans to export its anti-snake venom serum [1]

Core Viewpoint - The company announced a cash dividend distribution of CNY 0.12 per share for the first half of 2025, totaling CNY 12,986,400 [2][4]. Distribution Plan - The profit distribution plan was authorized by the shareholders' meeting on May 16, 2025, and approved by the board meeting on August 25, 2025 [2][3]. - The distribution is based on a total share capital of 108,220,000 shares [4]. - The cash dividend will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [3]. Implementation Details - The cash dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited [5]. - Shareholders who have not completed designated trading will have their dividends held by the clearing company until the designated trading is completed [5]. Taxation Information - For individual shareholders holding shares for over one year, the cash dividend is exempt from personal income tax, resulting in an actual distribution of CNY 0.12 per share [9]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution; tax will be calculated upon the transfer of shares [9]. - For Qualified Foreign Institutional Investors (QFII), a 10% withholding tax will apply, resulting in a net distribution of CNY 0.108 per share [10]. - Hong Kong investors will also receive a net distribution of CNY 0.108 per share after a 10% withholding tax [11]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the company's board secretary office at 021-64959122 [12].

Group 1 - The company announced a cash dividend of 0.12 yuan per share (including tax) for the first half of 2025 [2] - The record date for the dividend is set for September 25, 2025 [2] - The ex-dividend date and the date of cash dividend distribution are both scheduled for September 26, 2025 [2]

证券代码：688163 证券简称：赛伦生物 公告编号：2025-027 上海赛伦生物技术股份有限公司 2025年半年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 相关日期 | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/9/25 | 2025/9/26 | 2025/9/26 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经公司2025 年 5 月 16 日的2024年年度股东会授权董事会制 定，并经公司 2025 年 8 月 25 日召开的第四届董事会第八次会议审议通过后实施。 二、 分配方案 1. 发放年度：2025年半年度 2. 分派对象： 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 3. 分配方案： 本次利润分配以方案实施前的公司总股本108,220,000股为基数，每股派发现 金红利0.12元（含税），共 ...

Summary of Key Points Core Viewpoint - On September 11, a total of 9 companies had their restricted shares unlocked, with a total unlock volume of 114 million shares, amounting to a market value of 3.989 billion yuan based on the latest closing price [1]. Group 1: Unlock Volume - Two companies had unlock volumes exceeding 10 million shares: Sailun Biotech with 63.848 million shares and Qingmu Technology with 16.8263 million shares [1]. - The third company with significant unlock volume is Shida Group, which had 9.425 million shares unlocked [1]. Group 2: Unlock Market Value - Two companies had unlock market values exceeding 100 million yuan: Sailun Biotech with 1.567 billion yuan and Qingmu Technology with 1.119 billion yuan [1]. - The third company with a notable unlock market value is Huihan Co., which had an unlock market value of 685 million yuan [1]. Group 3: Unlock Ratio - Two companies had unlock ratios exceeding 10%: Sailun Biotech with 59.0% and Qingmu Technology with 18.18% [1]. - The third company with a significant unlock ratio is Haisheng Pharmaceutical, which had an unlock ratio of 7.38% [1].

Group 1 - The company has initiated two new drug research projects in the first half of 2025, focusing on broad-spectrum anti-snake venom antibodies and recombinant snake venom coagulase, currently in the laboratory research phase [1] - The company's export of anti-snake venom serum raw liquid to South Korea is noted, with both the export business amount and its proportion in operating revenue being very small [1] - Specific data regarding overseas operating revenue can be referenced in the company's annual reports [1]

Summary of Key Points Core Viewpoint - On August 27, 2023, Siron Biotech's stock fell by 5.18%, with a trading volume of 89.71 million yuan, indicating a potential concern among investors regarding the company's performance and market sentiment [1]. Financing and Trading Data - On the same day, Siron Biotech had a financing buy amount of 8.79 million yuan and a financing repayment of 14.48 million yuan, resulting in a net financing buy of -5.68 million yuan [1]. - As of August 27, the total financing and securities lending balance for Siron Biotech was 152 million yuan, which represents 13.58% of its market capitalization [1]. - The financing balance is at a high level, exceeding the 90th percentile of the past year [1]. - There were no shares sold or repaid in the securities lending segment on August 27, indicating a lack of short-selling activity [1]. Company Overview - Siron Biotech, established on November 9, 1999, and listed on March 11, 2022, is based in Qingpu District, Shanghai [1]. - The company specializes in the research, development, production, and sales of preventive and therapeutic drugs related to biological toxins and biosafety [1]. - The main business revenue is derived entirely from antiserum and antitoxin products, accounting for 100% of its income [1]. Financial Performance - As of June 30, 2025, Siron Biotech reported a total of 7,724 shareholders, an increase of 9.39% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 8.58% to 5,744 shares [2]. - For the first half of 2025, the company achieved an operating income of 101 million yuan, reflecting a year-on-year growth of 2.82% [2]. - The net profit attributable to the parent company was 32.98 million yuan, also showing a year-on-year increase of 2.07% [2]. - Since its A-share listing, Siron Biotech has distributed a total of 235 million yuan in dividends, with 137 million yuan distributed over the past three years [2]. - Notably, as of June 30, 2025, a significant institutional shareholder, Southern Science and Technology Innovation Board 3-Year Open Mixed Fund, has exited the top ten circulating shareholders list [2].

Domestic News - A total of 40 listed companies in the A-share market will have their restricted shares unlocked next week, with a combined market value of approximately 966.01 billion yuan. The companies with the highest unlock values include Times Electric (278.23 billion yuan), Southern Power Storage (230.81 billion yuan), and BGI Genomics (133.82 billion yuan) [1] - The unlock ratios for several companies exceed 50%, with Minshida at 66.23%, Southern Power Storage at 65.3%, Sailun Biotech at 59%, and Zhejiang Hengwei at 50.95% [1] International News - The 24th Economic Ministers' Meeting of the Shanghai Cooperation Organization (SCO) was held in Vladivostok, Russia, focusing on sustainable economic growth measures and planning for future regional economic cooperation [2] - The price of domestic gold jewelry has surpassed 1,060 yuan per gram, with brands like Chow Sang Sang and Lao Miao reporting increases in their gold prices [3] - The completion of the first main tower of the Zhuhai Bridge, which connects Zhoushan's Liuhong Island and Foduo Island, marks a significant milestone in infrastructure development, with a main span of 1,768 meters [3]